Dialyfix®
Our mission is to improve the quality of life of dialysis patients through innovation and patient-centered care.
According to the International Society of Nephrology between 5 and 10 million end-stage kidney disease (ESKD) patients need hemodialysis for treatment.
As recommended by the current clinical practice guidelines (KDOQI), the arteriovenous fistula ("AVF" or "fistula") is the preferred method of vascular access for hemodialysis.
However, this method potentially leads to fistula-related complications, including 30%-60% non-maturation rate, stenosis, thrombosis, infections, with 30% of hemodialysis patients being hospitalized as a result.
Annual healthcare expenditures related to ESRD amount to 34+ billion USD in the USA alone, a significant portion of which is related to the creation and maintenance of AVFs.
To improve patient welfare and decrease healthcare expenditures, there is a need to reduce fistula-related complications.